Form 4: Co-Diagnostics Director Reports Stock Transactions

Eugene Durenard, a Director at Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock.

Summary

• Eugene Durenard, a Director at Co-Diagnostics, Inc., filed a Form 4 reporting changes in beneficial ownership.
• On May 23, 2026, 1,695 shares of Common Stock were acquired at a price of $0.00.
• Following this transaction, Durenard beneficially owns 10,668 shares of Common Stock directly.
• The filing also details the acquisition of 1,695 restricted stock units (RSUs) on May 23, 2026, with a value of $0.00.
• These RSUs are part of awards granted on June 12, 2023, April 26, 2024, and August 13, 2025, vesting in six equal installments every six months.
• The earliest transaction date noted in the filing is May 27, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider stock transactions and RSU awards rather than significant strategic or financial developments.

Positives

• Director Eugene Durenard acquired 1,695 shares of common stock at no cost.
• The acquisition of restricted stock units indicates continued equity-based compensation for the director.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently signal strategic shifts, but they provide transparency into executive and director equity holdings and movements.

Stakeholder Impact

• Shareholders gain transparency into director's equity transactions.

Key Dates

Keywords

Form 4, SEC Filing, Co-Diagnostics, CODX, Insider Trading, Stock Transaction, Restricted Stock Units, Beneficial Ownership, Director